North America holds a dominant position in the global viral vector and plasmid DNA manufacturing market due to the presence of advanced healthcare infrastructure, strong regulatory frameworks, and significant investments in biotechnology research. The region benefits from a high concentration of biopharmaceutical companies, increasing clinical trial activities, and growing demand for gene and...